Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.48 |
| ▸ | NOS3 | P29474 | 7/20 | 0.48 |
| ▸ | NOS2 | P35228 | 5/20 | 0.48 |
| ▸ | HTR7 | P34969 | 5/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833803 | 0.85 | NOS3 (0.67) | NOS1NOS3NOS2HTR7HTR1B | |
| SCHEMBL6152658 | 0.82 | NOS3 (0.68) | NOS1NOS3NOS2HTR7HTR1B | |
| SCHEMBL252053 | 0.80 | NOS1 (0.73) | NOS1NOS3NOS2HTR7 | |
| SCHEMBL6583126 | 0.77 | NOS3 (0.50) | NOS1NOS3NOS2HTR7HTR1B | |
| SCHEMBL7083838 | 0.73 | NOS3 (0.51) | NOS1NOS3NOS2 | |
| SCHEMBL27981576 | 0.72 | NOS3 (0.44) | NOS1NOS3NOS2HTR7HTR1B | |
| SCHEMBL6584801 | 0.72 | AR (0.34) | KDM4E | |
| SCHEMBL7086013 | 0.71 | NOS3 (0.49) | NOS1NOS3NOS2KDM4EFLT3 | |
| SCHEMBL6583121 | 0.71 | NOS3 (0.44) | NOS1NOS3NOS2HTR7HTR1B | |
| SCHEMBL5833350 | 0.69 | PTGER1 (0.42) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0958282-B1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PROD INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
| EP-0958282-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | Pfizer Products Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998034919-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PRODUCTS INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | NOS1 1/4885NOS3 4/4885NOS2 3/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | NOS1 2484/4885NOS3 2496/4885NOS2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.